6-[2-[5-氯-2-[(2,4-二氟苯基)甲氧基]苯基]环戊烯-1-基]吡啶-2-羧酸 | 612831-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-[2-[5-氯-2-[(2,4-二氟苯基)甲氧基]苯基]环戊烯-1-基]吡啶-2-羧酸
• 英文名称: GW848687X
• 英文别名: 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-p yridinecarboxylic acid；6-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-1-cyclopentenyl]pyridine-2-carboxylic Acid；6-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]cyclopenten-1-yl]pyridine-2-carboxylic acid
• CAS: 612831-24-0
• 化学式: C₂₄H₁₈ClF₂NO₃
• 分子量: 441.862
• InChiKey: PFODPHDNBFSMOX-UHFFFAOYSA-N

物化性质

• 沸点：
  622.8±55.0 °C(Predicted)
• 密度：
  1.393±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：5 mg/ml； DMSO：3 mg/ml；乙醇：10 mg/ml；乙醇:PBS (pH 7.2) (1:3): 0.25 mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-[2-[5-氯-2-[(2,4-二氟苯基)甲氧基]苯基]环戊烯-1-基]吡啶-2-羧酸 以 水 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  A spectroscopic and computational study of an electrocyclized photo-degradation product of 6-(2-(5-chloro-2-(2,4-difluorobenyzloxy)phenyl)cyclopent-1-enyl)picolinic acid

  摘要：

  An unusual electrocyclized photo-degradation product of an EP1 antagonist drug candidate, 6-(2-(5-chloro-2-(2,4-difluorobenyzloxy) phenyl) cyclopent-1-enyl) picolinic acid, is characterized by liquid chromatography (LC) with mass spectrometry (MS) and NMR. LC-MSn experiments using electrospray ionization are used to obtain a tentative structure of the photo-degradation product from fragmentation studies, exchangeable proton analysis, and accurate mass data. H-1 LC-NMR, including nuclear Overhauser effect experiments, are performed in stopped-flow mode to confirm the structure. A small amount of material was isolated via preparative chromatography for 2D C-13 NMR analysis. The H-1 and C-13 NMR shifts of the photo-degradation product are calculated and compared to experimental values using density functional theory (DFT) to confirm the structural assignment. Several interesting features of the MS fragmentation of the photo-degradation product are examined and explained using DFT methods, including the transition state of an intramolecular Smiles rearrangement. The UV-Visible (UV-Vis) spectrum of the photo-degradation product is also predicted using time-dependent DFT (TDDFT) and matched to experimental data. A mechanism for the formation of this unusual photo-degradation product via electrocyclization is proposed and discussed. The combination of LC-MS, LC-NMR, and computational methods are used to provide a thorough structural identification of the photo-degradation product and also fully interpret the observed NMR, UV-Vis, and MS spectra. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molstruc.2010.09.036
• 作为产物：
  描述：

  ethyl 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylate 在 sodium hydroxide 、 乙醇 、 水 、 盐酸 作用下， 以 水 为溶剂， 反应 1.0h， 生成 6-[2-[5-氯-2-[(2,4-二氟苯基)甲氧基]苯基]环戊烯-1-基]吡啶-2-羧酸
  参考文献：
  名称：

  [EN] CYCLOPENTENE COMPOUNDS
  [FR] COMPOSES DE CYCLOPENTENE

  摘要：

  式（I）的化合物或其药用可接受的衍生物：其中A、B、Z、R1、R2a、R2b、R8、R9和Rx如规范中定义的那样，一种制备这种化合物的方法，包含这种化合物的药物组合物以及这种化合物在医学中的用途。

  公开号：

  WO2005037793A1

文献信息

• [EN] EP1 RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RÉCEPTEUR EP1
  申请人：ESTEVE LABOR DR

  公开号：WO2013037960A1

  公开（公告）日：2013-03-21

  The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

  本发明属于EP1受体配体领域。更具体地，它涉及具有对EP1受体具有很高亲和力和选择性的一般式(I)化合物。该发明还涉及它们的制备方法，以及它们作为治疗和/或预防由EP1受体介导的疾病或紊乱的药物的用途，以及包含它们的药物组合物。
• [EN] SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS POSSÉDANT UNE ACTIVITÉ CONTRE LES RÉCEPTEURS EP1
  申请人：ALMIRALL SA

  公开号：WO2013149997A1

  公开（公告）日：2013-10-10

  The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

  本发明属于EP1受体配体领域。更具体地，它涉及具有对EP1受体具有很高亲和力和选择性的一般式(I)化合物。该发明还涉及它们的制备方法，以及它们作为药物用于治疗和/或预防由EP1受体介导的疾病或紊乱，以及包含它们的药物组合物。
• Substituted tricyclic compounds with activity towards ep1 receptors
  申请人：Almirall, S.A.

  公开号：EP2647638A1

  公开（公告）日：2013-10-09

  The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

  本发明属于EP1受体配体领域。更具体地，它涉及具有对EP1受体具有很高亲和力和选择性的一般式(I)化合物。该发明还涉及它们的制备过程，以及它们作为治疗和/或预防由EP1受体介导的疾病或紊乱的药物的用途，以及包含它们的药物组合物。
• Ep1 receptor ligands
  申请人：Almirall, S.A.

  公开号：EP2570125A1

  公开（公告）日：2013-03-20

  The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

  本发明属于EP1受体配体领域。更具体地说，它涉及具有对EP1受体具有高亲和力和选择性的一般式(I)化合物。本发明还涉及它们的制备过程，它们作为治疗和/或预防由EP1受体介导的疾病或障碍的药物的使用，以及包含它们的制药组合物。
• (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives
  申请人：Giblin Paul Gerard Martin

  公开号：US20050239802A1

  公开（公告）日：2005-10-27

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R 1 , R 2 , R x , R 8 , R 9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  公式（I）的化合物或其药学上可接受的衍生物：其中A，R1，R2，Rx，R8，R9和n如规范中所定义，制备这种化合物的过程，包括这种化合物的制药组合物以及在医学中使用这种化合物的用途。